Cassava Sciences | PTIE - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Abbott USD 5.86B 675M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cassava Sciences USD -3.96M 1.16M 2025-09
Eisai JPY 153.41B 15.44B 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Geron USD 50.14M 3.44M 2026-03
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12